Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis and Orthotopic Liver Transplantation

American Journal of Transplantation

Volumn 4, Issue 5, 2004, Pages 686-693

  Burke, Anne ^a   Lucey, Michael R ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Fatty liver disease; Insulin resistance; Liver transplantation; Obesity; Oxidative stress

Indexed keywords

COMORBIDITY; DEVELOPING COUNTRY; DIABETES MELLITUS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONOR; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; SHORT SURVEY; TREATMENT OUTCOME;

FATTY LIVER; GRAFT SURVIVAL; HEPATITIS; HUMANS; INSULIN RESISTANCE; LIVER TRANSPLANTATION; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 2442545703     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00432.x     Document Type: Short Survey

References (81)

1. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-1110.
2. Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a 'normal' population - examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977; 12: 593-597.
3. Neuschwander-Tetri B, Caldwell S. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219.
4. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-1109.
5. Garcia-Monzon C, Martin-Perez E, Iacono OL et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity [comment]. [erratum appears in J Hepatol 2001; 34: 180]. J Hepatol 2000; 33: 716-724.
6. Garcia-Monzon C, Martin-Perez E, Iacono OL et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity [comment]. [erratum appears in J Hepatol 2001; 34: 180]. J Hepatol 2000; 33: 716-724.
7. Ratziu V, Giral P, Charlotte F et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.
8. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669.
9. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese [comment]. Gastroenterology 2001; 121: 91-100.
10. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000 [comment]. JAMA 2002; 288: 1723-1727.
11. Defining Overweight and Obesity. National Center for Chronic Disease Prevention and Health Promotion, 2003. [http://www.cdc.gov/nccdphp/bb.nutrition/index.htm].
12. International Obesity Task Force Secretariat. The Global Challenge of Obesity and the International Obesity Task Force. [WWW document] URL http://www.iuns.org/features/obesity/obesity.htm. 2002.
13. National Center for Infectious Diseases. Viral Hepatitis C. fact sheet. [WWW document] URL http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm. 2003.
14. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
15. Evans CD, Oien KA, MacSween RN, Mills PR. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol 2002; 55: 689-692.
16. Angulo P, Keach JC, Batts K, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
17. Adams LA, Keach JC, Lindor KD, Angulo P. Time course of fibrosis progression in patients with nonalcoholic fatty liver disease. Hepatology 2003; 38: 206A-207A [Abstract].
18. Saksena S, Day CP, James OFW. Natural history and determinants of disease progression in non alcoholic fatty liver disease. Good and bad news. Hepatology 2003; 38: 232A [Abstract].
19. Charlton M, Kasparova P, Weston S et al. Frequency of nonalcoholic steatohepatis as a cause of advanced liver disease. Liver Transpl 2001; 7: 608-614.
20. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case control study. Hepatology 2000; 32: 689-692.
21. Liver Transplant Waiting List. UNOS database 2000. [http://www.optn.org/] URL.
22. European Liver Transplant Network. Primary Indication of Liver Transplantation in Cirrhosis in Europe. [WWW document] URL http://www.eltr.org/result8.htm. 2002.
23. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002; 97: 2408-2414.
24. Raynard B, Balian A, Falik D et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002; 35: 635-658.
25. Ioannou GN, Weiss NS, Kwodley KV, Dominitz JA. Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. Gastroenterology 2003; 125: 1053-1059.
26. Organ Procurement and Transplant Network. www. OPTN.org 2003, 10-29-, 2003. Ref Type: Electronic Citation.
27. Schunkert H. Obesity and target organ damage: the heart. Int J Obes Relat Metab Disord 2002; 26: S15-S20.
28. Day CP, James OFW. Steatohepatitis: a tale of two hits? Gastroenterology 1998; 114: 842-845.
29. Chittuir S, Abeygunasekea S, Farrell GC et al. NASH an insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379.
30. Pagano G, Pacini G, Musso G et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology 2002; 35: 367-372.
31. Borona E, Coscelli C, Orioli S et al. Hyperinsulinemia of chronic active hepatitis: impaired insulin removal rather than pancreatic hypersecretion. Horm Metab Res 1984; 16: 111-1114.
32. Sanyal AJ, Cambpell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192.
33. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002; 37: 56-62.
34. Keaney JF, Larson MG, Vasan RS et al. obesity and systemic oxidative stress clinical correlates of oxidative stress in the Framingham Study. Arterioscler, Thromb Vasc Biol 2003; 23: 434-439.
35. Gopaul NK, Manraj MD, Hebe A et al. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 2001; 44: 706-712.
36. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999; 245: 621-625.
37. Tsigos C, Kyrou I, Chala E et al. Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism 1999; 48: 1332-1335.
38. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-668.
39. Fernandez-Checa, JC, Kaplowitz, N, Garcia-Ruiz, C et al. GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am J Physiol 1997; 273: G7-G17.
40. Watt KDS, Lyden ER, McCashland TM. Poor survival after liver retransplantation: Is hepatitis C to blame. Liver Transpl 2003; 9: 1019-1024.
41. Imber CJ, St Peter SD, Lopez I, Guiver L, Friend PJ. Current practice regarding the use of fatty livers: a trans-atlantic survey. Liver Transpl 2002; 8: 545-549.
42. Imber CJ, St Peter SD, Handa A, Friend PJ. Hepatic steatosis and its relationship to transplantation. Liver Transpl 2002; 8: 415-423.
43. Trotter JF. Thin chance for fat people to become living donors. Liver Transpl 2001; 7: 415-417.
44. Brandhagen D, Fidler J, Rosen CB. Evaluation of the donor for living donor liver transplantation. Liver Transpl 2003; 9: S16-S28.
45. Rinella ME, Alonso E, Rao S et al. Body mass index as a predictor of hepatitic steatosis in living liver donors. Liver Transpl 2001; 7: 409-414.
46. Ryan CK, Johnson LA, Germin BI, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 2002; 8: 1114-1122.
47. Kamal M, Lassman CR, Ghobrial RM, Saab S, Marks K, Busuttil R. Histologic findings in potential living liver donor biopsies. Hepatology 2003; 38: 650A [Abstract].
48. Marsman WA, Wiesner RH, Rodriguez L et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996; 62: 1246-1251.
49. Fishbein TM, Fiel IM, Emre S et al. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997; 64: 248-251.
50. Urena MA, Moreno GE, Romero CJ, Ruiz-Delgado FC, Moreno SC. An approach to the rational use of steatotic donor livers in liver transplantation. Hepato-Gastroenterology 1999; 46: 1164-1173.
51. Chavin KD, Yang SQ, Lin HZ et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999; 274: 5692-5700.
52. Cortez-Pinto H, Lin HZ, Yang SQ, Da Costa SO, Diehl AM. Lipids upregulate uncoupling protein 2 expression in rat hepatocytes. Gastroenterology 1999; 116: 1184-1193.
53. Cisneros C, Guillen F, Gomez R et al. Analysis of warm ischaemia time for prediction of primary nonfunction of the hepatic graft. Transplant Proc 1991; 23: 1976.
54. Fukumori T, Ohkohchi N, Tsukamoto S, Satomi S. The mechanisms of injury in a steatotic liver graft during cold preservation. Transplantation 1999; 67: 195-200.
55. Hui AM, Kawasaki S, Makuuchi M, Nakayama J, Ikegami T, Miyagawa S. Liver injury following normothermic ischemia in steatotic rat liver. Hepatology 1994; 20: 1287-1293.
56. Todo S, DeMetris AJ, Makowka L et al. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989; 47: 903-905.
57. Wada K, Fujimoto K, Fujikawa Y, Shibayama Y, Mitsui H, Nakata K. Sinusoidal stenosis as the cause of portal hypertension in choline deficient diet induced fatty cirrhosis of the rat liver. Acta Pathol Japon 1974; 24: 207-217.
58. Letteron P, Fromenty B, Thomas P, Degott C, Pessayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996; 24: 200-208.
59. Laight DW, Desai KM, Gopaul NK, Anggard EE, Carrier MJ. F2-isoprostane evidence of oxidant stress in the insulin resistant, obese Zucker rat: effects of vitamin E. Eur J Pharmacol 1999; 377: 89-92.
60. Soltyl K, Dikdan G, Koneru B. Oxidative stress in fatty livers of obese Zucker rats: rapid amelioration and improved tolerance to warm ischemia with tocopherol. Hepatology 2003; 34: 13-18.
61. Shields PL, Tang H, Neuberger JM, Gunson BK, McMaster P, Pirenne J. Poor outcome in patients with diabetes mellitus undergoing liver transplantation. Transplantation 1999; 68: 530-535.
62. Contos MJ, Cales W, Sterling RK et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7: 363-373.
63. Nair SP, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35: 105-109.
64. Morris CK, Ueshima K, Kawaguchi T et al. The prognostic value of exercise capacity: a review of the literature. Am Heart J 1991; 122: 1423-1431.
65. Ramsay MAE, Simpson BR, Nguyen A-T, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997; 3: 494-500.
66. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6: 443-450.
67. Cauble MS, Gilroy R, Sorrell MF et al. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation 2001; 71: 892-895.
68. Molloy RM, Komorowski R, Varma RR. Recurrent nonalcoholic steatothepatitis and cirrhosis after liver transplantation. Liver Transplantation and Surgery 1997; 3: 117-178.
69. Burke, A. Medical management of the liver transplant patient. In: Lucey MR, Shaked A, Neuberger JM, eds. Liver Transplantation. Texas: Landes Bioscience; 2003: 98-108.
70. Marchetti P, Navalesi R. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest 2000; 23: 482-490.
71. 2 isoprostanes in hypercholesterolemia. Circulation 1998; 98: 2822-2828.
72. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001; 108: 635-636.
73. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001; 17: 189-212.
74. Burke A, FitzGerald GA, Lucey MR. A prospective analysis of oxidative stress and liver transplantation. Transplantation 2002; 74: 217-221.
75. Neuschwander-Tetri BA, Brunt E, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-ligand rosiglitazone. Hepatology 2003; 38: 1008-1017.
76. American Gastroenterological Association medical position statement: Nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1702-1704.
77. Bogardus C, Lillioja S, Mott DM, Hollenbeck C, Reaven GM. Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol 2003; 248: E286-E291.
78. Painter P, Krasnoff J, Paul SM, Ascher NL. Physical activity and health-related quality of life in liver transplant recipients. Liver Transpl 2001; 7: 213-219.
79. Fassio E, Alvarez E, Dominquez N, Landeira G, Longo C. Expanding knowledge of natural history of non-alcoholic steatohepatitis: a longitudinal study of sequential biopsies. Hepatology 2003; 38: 231A-157.
80. GreenLee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001; 51: 15-36.
81. Jones CA, McQuillan GM, Kusek JW et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998; 32: 992-999.